Mölnlycke recognised with EUPD’s ‘ESG Transparency Award
We are delighted to announce that Mölnlycke was recognised with ‘ESG Transparency Award' by EUPD Research. Mölnlycke achieved the highest excellence level with the total score of 95,5%.
The companies are assessed based on ESG Transparency Evaluation Standard developed by EUPD Research. The evaluation criteria are divided into three categories:
- Transparency (45%) – evaluates clarity, structure and accessibility of ESG reporting, including target setting, progress measurement and addressing relevant stakeholders.
- Environmental, Social, Governance (45%) – covers topics such as working conditions, diversity and inclusion, health and safety, community engagement and supply chain responsibility.
- Regulatory landscape (10%) – measures compliance with European guidelines and international standards or initiatives, including the timelines of reporting.
Mölnlycke has also been recognised as a Leading Company due to its high score in every category.
‘We’re proud to be recognised for the strength of our ESG reporting — because reliable and transparent data drives better decisions, innovation, and sustainable growth for people and planet,’ comments Caterina Camerani, VP Sustainability
About EUPD Research
EUPD Research offers comprehensive insights into the transparency status of sustainability reporting. With over 20 years of experience in data collection and analysis, the ESG Transparency Evaluation Standard provides organsations with an individualised evaluation report that highlights their current transparency level in ESG reporting. The analysis is based on thousands of verified ESG reports from all European countries and across all industry classifications.
Latest news
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold Strategic Partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.